Four Ring Pharmaceuticals: Seventh batch of nationwide nationwide drug concentrated procurement of five products

On July 21, 2022, Four Ring Pharmaceuticals (00460.HK) issued an announcement. Among the five products of the group selected seventh batch of nationwide nationwide centralized procurement, including: 1ml: 0.1mg), pomocarbolinol Tonofovir tablets (25mg), sulfidal sodium sodium injection (0.5ml: 2.5mg), Lago sesamine (50 mg), and amber acid mitolol most -release tablets (47.5mg).

According to the announcement, the acetic acid octon peptide injection (1ml: 0.1mg) is mainly used to treat the symptoms of limb hyperants, alleviate the symptoms of endocrine tumors of gastrointestinal pancreas, prevent complications of post -pancreatic surgery, and gastroesophageal vein bleeding. Medical insurance products B products. According to IQVIA data, in 2021, the product sales in China's public hospitals were about RMB 1.9 billion.

Femaicol picotol is a high -efficiency anti -hepatitis B drug, which belongs to the national medical insurance products. According to IQVIA data, from 2019 to 2021, the average annual growth rate of terminal sales in public hospitals in China reached 376.51%.

Sulfa liver sodium injection (0.5ml: 2.5mg) for patients with major orthopedic surgery such as hip fracture surgery, major knee joint surgery, or hip joint replacement. Class B products. According to IQVIA data, from 2019 to 2021, the average annual growth rate of terminal sales in Chinese public hospitals reached 130.52%.

Latokosamine (50mg) is used for the combined treatment of partial seizures of patients with epilepsy over 16 years of age and above. It belongs to national medical insurance products. According to IQVIA data, from 2020 to 2021, the sales of terminal sales in Chinese public hospitals increased by 363.92%year -on -year.

Amber acid Meetolol Smoil (47.5mg) is mainly used to treat chronic heart failure with stable symptoms with abnormal symptoms of hypertension, angina pectoris, and left ventricular contraction function, which belongs to national medical insurance products. According to IQVIA data, from 2019 to 2021, the terminal sales in Chinese public hospitals were 2.2 billion yuan, 2.5 billion yuan, and 2.8 billion yuan, respectively.

Four Ring Pharmaceuticals was founded in 2001. It was listed on the main board of Hong Kong United Trading Co., Ltd. in 2010. It is a leading independent research and development technology platform, with an independent leading -leading independent research and development technology platform, rich global product pipelines, product registration capabilities, full -time dosage formats International pharmaceutical and medical beauty enterprises of production platform and sales system.

As of the time, Four Ring Pharmaceuticals fell 1.65%to HK $ 1.19, and the latest market value was HK $ 11.1 billion.

- END -